![Øyvind Kongstun Arnesen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Øyvind Kongstun Arnesen
Directeur Général chez
VITMED AS
Profil
Øyvind Kongstun Arnesen currently works at VITMED AS, as Chief Executive Officer & Director, Oslo Cancer Cluster NCE, as Chairman, Curida AS, as Director, and Cytovation AS, as Director from 2022.
Mr. Arnesen also formerly worked at Hubro Therapeutics AS, as Chairman & Chief Executive Officer from 2021 to 2024, Ultimovacs ASA, as Chief Executive Officer, Boehringer Ingelheim Norway KS, as Medical Director & Head-Clinical Operations from 2007 to 2012, Bristol-Myers Squibb Norway AS, as Medical Director from 2004 to 2007, and AstraZeneca AS, as Clinical Trial Manager from 1995 to 1996.
Mr. Arnesen received his doctorate degree from the University of Oslo.
Postes actifs de Øyvind Kongstun Arnesen
| Sociétés | Poste | Début |
|---|---|---|
Oslo Cancer Cluster NCE
 Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Operates as oncology research firm, which develops cancer diagnostics and medicines | Président | - |
VITMED AS | Directeur Général | - |
Cytovation AS
 Cytovation AS Miscellaneous Commercial ServicesCommercial Services Develops and researches on dermatological diseases | Directeur/Membre du Conseil | 15/09/2022 |
Curida AS
 Curida AS Pharmaceuticals: MajorHealth Technology Manufactures and markets nasal and inhalation drug products | Directeur/Membre du Conseil | - |
Anciens postes connus de Øyvind Kongstun Arnesen
| Sociétés | Poste | Fin |
|---|---|---|
Hubro Therapeutics AS
 Hubro Therapeutics AS BiotechnologyHealth Technology Develops immunotherapies and neo-antigen vaccines for treatment of cancer | Directeur Général | 01/06/2024 |
Ultimovacs ASA
 Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Directeur Général | 01/06/2020 |
Boehringer Ingelheim Norway KS | Directeur Technique/Scientifique/R&D | 01/01/2012 |
Bristol-Myers Squibb Norway Ltd. | Directeur Technique/Scientifique/R&D | 01/01/2007 |
AstraZeneca AS | Corporate Officer/Principal | 01/01/1996 |
Formation de Øyvind Kongstun Arnesen
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
14
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Oslo Cancer Cluster NCE
Oslo Cancer Cluster NCE Miscellaneous Commercial ServicesCommercial Services Operates as oncology research firm, which develops cancer diagnostics and medicines | Commercial Services |
AstraZeneca AS | |
University of Oslo
 University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Boehringer Ingelheim Norway KS | |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Health Technology |
Curida AS
Curida AS Pharmaceuticals: MajorHealth Technology Manufactures and markets nasal and inhalation drug products | Health Technology |
Bristol-Myers Squibb Norway Ltd. | |
Cytovation AS
Cytovation AS Miscellaneous Commercial ServicesCommercial Services Develops and researches on dermatological diseases | Commercial Services |
VITMED AS | |
Hubro Therapeutics AS
Hubro Therapeutics AS BiotechnologyHealth Technology Develops immunotherapies and neo-antigen vaccines for treatment of cancer | Health Technology |
